CD3G
T-cell surface glycoprotein CD3 gamma chain
As of the edition of 20 October 2026, CD3G (T-cell surface glycoprotein CD3 gamma chain, UniProt P09693) has 13 drugs tested at it and 9 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09693
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 37
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Infections; Lungs and airways; Nervous system; Urinary and reproductive
- Registered trials of its drugs
- 454
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Blinatumomab | Marketed | Phase 4 | Ends 2031 |
| Epcoritamab | Marketed | Phase 3 | Ends 2035 |
| Teclistamab | Marketed | Phase 4 | Ends 2034 |
| Mosunetuzumab | Marketed | Phase 3 | Ends 2034 |
| Talquetamab | Marketed | Phase 4 | Ends 2035 |
| Tarlatamab | Marketed | Phase 3 | Ends 2036 |
| Linvoseltamab | Marketed | Phase 4 | Ends 2037 |
| Odronextamab | Marketed | Phase 3 | none listed |
| Catumaxomab | Marketed | Phase 3 | none listed |
| Foralumab | Active | Phase 2 | none listed |
| Flotetuzumab | Stopped | Phase 2 | none listed |
| FBT-A05 | Stopped | Phase 2 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 9 |
| Total on the list | 9 |